Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.[1] It acts against interleukin 31(IL-31),[2] which is a cytokine involved in causing itchiness (pruritus).[2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.[3]
The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016,[3] and it was approved by the European Medicines Agency in 2017.[4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.[4]
https://en.wikipedia.org/wiki/Lokivetmab
No comments:
Post a Comment